SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Duramed (DRMD) Synthetic Estrogen Product -- Ignore unavailable to you. Want to Upgrade?

To: Wendisman who wrote (984)3/26/1999 1:04:00 PM
From: Chisy  Read Replies (1) | Respond to of 1837
 
Premarin is prescribed mainly to address two problems: Heart attacks and bone loss. Has DRMD addressed these problems yet? I got the impression from the interview that the answer is no, or rather that further study and proof would be needed. In the meantime, I think many women will continue to take Premarin. Any thoughts?



To: Wendisman who wrote (984)3/26/1999 2:54:00 PM
From: Martin Posgay  Read Replies (3) | Respond to of 1837
 
Should be around $15 to $17 next week. Usually the fund managers wait until the price settles down to a stable level before jumping into the market.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News